NYSE · Healthcare · Medical Devices · USA
Stryker Corp is a large cap company (market value between $10 billion and $200 billion) in the Medical Devices industry.
Stryker Corporation manufactures and sells medical devices across two main segments: MedSurg and Neurotechnology, which includes surgical equipment, endoscopic systems, patient handling products, and neurosurgical devices; and Orthopaedics, comprising joint replacement implants, trauma products, and robotic-assisted surgical systems. The company markets its products to hospitals, doctors, and healthcare facilities globally through subsidiaries, branches, and distributors.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Stryker Corp stock.
Overvalued: intrinsic value $204.83 per share, market price $297.94, margin of safety -45.5% (as of 2026-10-19).
Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $204.83; the price of $297.94 is 45% above that value, and 77% of that value comes from beyond year five.
Leak Score: 60/100 on 12 of 12 signals (Faint Leak).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
26 more in this industry show a wider margin of safety.
SYK is overvalued (as of the 2026-10-19 close). Discounting its cash flows at 8.9% (average of 3 methods) values the shares at $204.83; the price of $297.94 is 45% above that value, and 77% of that value comes from beyond year five.
$204.83 per share (as of the 2026-10-19 close), against a market price of $297.94. That is a margin of safety of -45.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price asks for more growth than the company has delivered. It needs the future to beat the past. Yearly sales growth the price needs: 24.9%. Yearly sales growth it has sustained: 11.1%.
60 out of 100, which we rate "Faint Leak", on 12 of 12 value investing signals.